ES2662444T3 - Derivado de piridina - Google Patents
Derivado de piridina Download PDFInfo
- Publication number
- ES2662444T3 ES2662444T3 ES13854714T ES13854714T ES2662444T3 ES 2662444 T3 ES2662444 T3 ES 2662444T3 ES 13854714 T ES13854714 T ES 13854714T ES 13854714 T ES13854714 T ES 13854714T ES 2662444 T3 ES2662444 T3 ES 2662444T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- carbon atoms
- optionally substituted
- ring
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Abstract
Un derivado de piridina representado por la siguiente fórmula (I) o una sal farmacéuticamente aceptable del mismo, o un solvato del mismo: **(Ver fórmula)** en donde: A representa un enlace sencillo, un átomo de oxígeno, un átomo de azufre, NH o CH2; R1 representa un átomo de nitrógeno o CH; uno de X1 a X5 representa un átomo de nitrógeno y los cuatro restantes representan CR2; cada R2 representa independientemente un átomo de hidrógeno, un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alquenilo que tiene de 2 a 6 átomos de carbono, un grupo alquinilo que tiene de 2 a 6 átomos de carbono, un átomo de halógeno, un grupo trifluorometilo, un grupo difluorometilo, un grupo ciano, un grupo alquilcarbonilo que tiene de 2 a 7 átomos de carbono, un grupo alquilsulfonilo que tiene de 1 a 6 átomos de carbono, un grupo nitro, un grupo amino, un grupo dialquilamino que tiene de 1 a 6 átomos de carbono que pueden formar opcionalmente un anillo, un grupo formilo, un grupo hidroxilo, un grupo alcoxi que tiene de 1 a 6 átomos de carbono (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo, un grupo fenilo, un grupo ciclohexilo y un átomo de halógeno), un grupo alquiltio que tiene de 1 a 6 átomos de carbono, un grupo fenilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), o un grupo fenoxi (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), con la condición de que cuando dos de CR2 son adyacentes, los dos de R2 pueden estar unidos opcionalmente para formar un anillo; R3 representa un átomo de hidrógeno, un grupo alquilo que tiene de 1 a 6 átomos de carbono (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo, un grupo amino, un grupo dialquilamino que tiene de 1 a 6 átomos de carbono que pueden formar opcionalmente un anillo, un anillo de imidazol, un anillo de pirazol, un anillo de pirrolidina, un anillo de piperidina, un anillo de morfolina y un anillo de piperazina (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono y un grupo alquilsulfonilo que tiene de 1 a 6 átomos de carbono)), un grupo alquenilo que tiene de 2 a 6 átomos de carbono, un grupo alquinilo que tiene de 2 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo y un átomo de halógeno), un grupo alquilcarbonilo que tiene de 2 a 7 átomos de carbono, un grupo alquiltio que tiene de 1 a 6 átomos de carbono, un grupo alquilsulfinilo que tiene de 1 a 6 átomos de carbono, un átomo de halógeno, un grupo trifluorometilo, un grupo difluorometilo, un grupo ciano, un grupo fenilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), un grupo piridilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), un grupo fenoxi (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo alcoxi que tiene de 1 a 6 átomos de carbono y un átomo de halógeno), un grupo carboxilo o -CO2R5; R4 representa un grupo carboxilo, un grupo tetrazolilo, -CONHSO2R5, -CO2R5, o cualquiera de los siguientes sustituyentes: ...
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012250661 | 2012-11-14 | ||
PCT/JP2013/080706 WO2014077285A1 (ja) | 2012-11-14 | 2013-11-13 | ピリジン誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2662444T3 true ES2662444T3 (es) | 2018-04-06 |
Family
ID=50731196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13854714T Active ES2662444T3 (es) | 2012-11-14 | 2013-11-13 | Derivado de piridina |
Country Status (36)
Country | Link |
---|---|
US (2) | US9637469B2 (es) |
EP (2) | EP3339302A1 (es) |
JP (2) | JP5774238B2 (es) |
KR (1) | KR20150082194A (es) |
CN (2) | CN107721931A (es) |
AR (1) | AR093468A1 (es) |
AU (2) | AU2013345894B2 (es) |
BR (1) | BR112015010977A2 (es) |
CA (1) | CA2891408A1 (es) |
CL (1) | CL2015001279A1 (es) |
CY (1) | CY1120127T1 (es) |
DK (1) | DK2944633T3 (es) |
ES (1) | ES2662444T3 (es) |
HK (1) | HK1211940A1 (es) |
HR (1) | HRP20180451T1 (es) |
HU (1) | HUE037736T2 (es) |
IL (2) | IL238539A (es) |
LT (1) | LT2944633T (es) |
MA (1) | MA38078B1 (es) |
ME (1) | ME03016B (es) |
MX (1) | MX2015003672A (es) |
NO (1) | NO2944633T3 (es) |
NZ (1) | NZ708031A (es) |
PE (1) | PE20150974A1 (es) |
PH (1) | PH12015501037A1 (es) |
PL (1) | PL2944633T3 (es) |
PT (1) | PT2944633T (es) |
RS (1) | RS57090B1 (es) |
RU (1) | RU2640588C2 (es) |
SA (1) | SA515360431B1 (es) |
SG (2) | SG10201705852PA (es) |
SI (1) | SI2944633T1 (es) |
TW (1) | TWI666205B (es) |
UA (1) | UA117359C2 (es) |
WO (1) | WO2014077285A1 (es) |
ZA (1) | ZA201503322B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2948797A1 (en) * | 2014-05-13 | 2015-11-19 | Teijin Pharma Limited | Pyrazine derivatives |
SG11201609483YA (en) * | 2014-05-13 | 2016-12-29 | Teijin Pharma Ltd | Novel crystalline polymorphs of pyridine derivative and method for producing the same |
MX2018011214A (es) | 2016-03-15 | 2019-03-28 | Bayer Cropscience Ag | Sulfonamidas sustituidas para controlar plagas animales. |
CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
EP3466946B1 (en) | 2016-05-23 | 2023-08-30 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
TW201837036A (zh) | 2017-01-10 | 2018-10-16 | 德商拜耳廠股份有限公司 | 作為除害劑之雜環衍生物(一) |
EP3568395A1 (de) | 2017-01-10 | 2019-11-20 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
CN108658879A (zh) * | 2017-03-29 | 2018-10-16 | 天津药物研究院有限公司 | 一种urat1抑制剂及其制备方法和用途 |
CN109251184B (zh) * | 2017-07-13 | 2021-06-15 | 浙江海正药业股份有限公司 | 一种2-三氟甲基苯磺酰胺类衍生物的医药用途 |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
TWI820231B (zh) | 2018-10-11 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於製備經取代咪唑衍生物之方法 |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
JP2023501978A (ja) | 2019-11-07 | 2023-01-20 | バイエル・アクチエンゲゼルシヤフト | 動物害虫駆除用の置換スルホニルアミド |
CN116033828A (zh) | 2020-07-02 | 2023-04-28 | 拜耳公司 | 作为害虫防治剂的杂环衍生物 |
CN114315729B (zh) * | 2021-12-09 | 2024-01-26 | 大连理工大学 | 1-苄基-2,4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1599032A (en) | 1977-03-04 | 1981-09-30 | May & Baker Ltd | Imidazole derivatives having herbicidal activity |
JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
US4770689A (en) | 1986-03-10 | 1988-09-13 | Janssen Pharmaceutica N.V. | Herbicidal imidazole-5-carboxylic acid derivatives |
PL149675B1 (pl) * | 1986-03-10 | 1990-03-31 | Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5 | |
US4851424A (en) | 1986-06-06 | 1989-07-25 | Ciba-Geigy Corporation | 1-Phenyl-lower alkyl-imidazole 4- or 5-carboxamide compounds which are useful in the treatment of epilepsy |
DD260928A5 (de) * | 1986-06-06 | 1988-10-12 | Ciba-Geigy Ag,Ch | Verfahren zur herstellung neuer aralkylimidizolderivate |
JPH08119936A (ja) | 1994-10-18 | 1996-05-14 | Fujisawa Pharmaceut Co Ltd | 複素環式誘導体 |
IT1295405B1 (it) * | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
CN1466572A (zh) * | 2000-07-28 | 2004-01-07 | ס����ҩ��ʽ���� | 吡咯衍生物 |
EP1792614A1 (en) | 2001-02-22 | 2007-06-06 | Teijin Pharma Limited | Benzo[b]thiophene derivatives |
AU2003902828A0 (en) * | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
EP2842948A1 (en) * | 2007-11-27 | 2015-03-04 | Ardea Biosciences, Inc. | Novel compounds and compositions and methods of use |
US8450500B2 (en) * | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
MX2011002449A (es) | 2008-09-04 | 2011-05-25 | Ardea Biosciences Inc | Compuestos, composiciones y métodos para utilizar los mismos para modular niveles de ácido úrico. |
JP2010202575A (ja) * | 2009-03-03 | 2010-09-16 | Takeda Chem Ind Ltd | 複素環化合物 |
CN102548964B (zh) * | 2009-07-10 | 2014-09-24 | 通用医疗公司 | 不抑制肾上腺皮质类固醇合成的依托咪酯类似物 |
CN102035579B (zh) * | 2009-09-28 | 2014-09-03 | 夏普株式会社 | 信息反馈方法和用户设备 |
AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
JP5485811B2 (ja) * | 2010-06-23 | 2014-05-07 | 株式会社ジャパンディスプレイ | 双方向シフトレジスタ、及びこれを用いた画像表示装置 |
PE20131304A1 (es) * | 2010-08-11 | 2013-11-14 | Millennium Pharm Inc | Heteroarilos y sus usos |
-
2013
- 2013-11-13 UA UAA201505767A patent/UA117359C2/uk unknown
- 2013-11-13 SI SI201330943T patent/SI2944633T1/en unknown
- 2013-11-13 CN CN201710933918.5A patent/CN107721931A/zh active Pending
- 2013-11-13 WO PCT/JP2013/080706 patent/WO2014077285A1/ja active Application Filing
- 2013-11-13 PL PL13854714T patent/PL2944633T3/pl unknown
- 2013-11-13 CN CN201380059519.0A patent/CN104797570B/zh not_active Expired - Fee Related
- 2013-11-13 KR KR1020157008457A patent/KR20150082194A/ko not_active Application Discontinuation
- 2013-11-13 CA CA2891408A patent/CA2891408A1/en not_active Abandoned
- 2013-11-13 NZ NZ708031A patent/NZ708031A/en not_active IP Right Cessation
- 2013-11-13 SG SG10201705852PA patent/SG10201705852PA/en unknown
- 2013-11-13 AU AU2013345894A patent/AU2013345894B2/en not_active Ceased
- 2013-11-13 MX MX2015003672A patent/MX2015003672A/es unknown
- 2013-11-13 DK DK13854714.6T patent/DK2944633T3/en active
- 2013-11-13 US US14/441,074 patent/US9637469B2/en active Active
- 2013-11-13 LT LTEP13854714.6T patent/LT2944633T/lt unknown
- 2013-11-13 EP EP18152142.8A patent/EP3339302A1/en not_active Withdrawn
- 2013-11-13 BR BR112015010977A patent/BR112015010977A2/pt not_active Application Discontinuation
- 2013-11-13 PE PE2015000616A patent/PE20150974A1/es not_active Application Discontinuation
- 2013-11-13 EP EP13854714.6A patent/EP2944633B1/en active Active
- 2013-11-13 ME MEP-2018-91A patent/ME03016B/me unknown
- 2013-11-13 JP JP2014547007A patent/JP5774238B2/ja not_active Expired - Fee Related
- 2013-11-13 TW TW102141292A patent/TWI666205B/zh not_active IP Right Cessation
- 2013-11-13 ES ES13854714T patent/ES2662444T3/es active Active
- 2013-11-13 NO NO13854714A patent/NO2944633T3/no unknown
- 2013-11-13 RU RU2015122698A patent/RU2640588C2/ru active
- 2013-11-13 PT PT138547146T patent/PT2944633T/pt unknown
- 2013-11-13 SG SG11201503770VA patent/SG11201503770VA/en unknown
- 2013-11-13 HU HUE13854714A patent/HUE037736T2/hu unknown
- 2013-11-13 AR ARP130104172A patent/AR093468A1/es unknown
- 2013-11-13 RS RS20180390A patent/RS57090B1/sr unknown
- 2013-11-13 MA MA38078A patent/MA38078B1/fr unknown
-
2015
- 2015-01-16 JP JP2015007229A patent/JP6293068B2/ja not_active Expired - Fee Related
- 2015-04-30 IL IL238539A patent/IL238539A/en not_active IP Right Cessation
- 2015-05-08 PH PH12015501037A patent/PH12015501037A1/en unknown
- 2015-05-12 CL CL2015001279A patent/CL2015001279A1/es unknown
- 2015-05-13 SA SA515360431A patent/SA515360431B1/ar unknown
- 2015-05-13 ZA ZA2015/03322A patent/ZA201503322B/en unknown
- 2015-12-17 IL IL243193A patent/IL243193A0/en unknown
- 2015-12-31 HK HK15112873.0A patent/HK1211940A1/xx not_active IP Right Cessation
-
2017
- 2017-03-22 US US15/466,088 patent/US20170190694A1/en not_active Abandoned
- 2017-07-07 AU AU2017204665A patent/AU2017204665A1/en not_active Abandoned
-
2018
- 2018-03-16 HR HRP20180451TT patent/HRP20180451T1/hr unknown
- 2018-04-10 CY CY20181100389T patent/CY1120127T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2662444T3 (es) | Derivado de piridina | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
JO3425B1 (ar) | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
EA201291414A1 (ru) | Имидазопиридиновые производные, способ их получения и терапевтическое использование | |
AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
NZ710052A (en) | Novel pyrazol derivatives | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR097866A1 (es) | Derivados de 4-azaindol | |
MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
PH12016502358A1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR096152A1 (es) | Derivados de purina | |
ES2572052T3 (es) | Amidas macrocíclicas como inhibidores de proteasas | |
MX338631B (es) | 5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
MX2015013365A (es) | Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag). | |
AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN |